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1 Introduction 
A central problem in pharmacology is the relationship between the dose 
and subsequent effect of a drug; in particular, the relationship between a 
drug's concentration at the targeted or effects compartment and its observed 
response, see [14, 10] for instance. There are various technical and prac-
tical reasons as to why this is a challenging problem. Among them is the 
common situation involving human subjects; that is, it is not possible to 
administer a drug or sample at the targeted compartment, and hence it is 
not possible to directly relate the concentration in this compartment to its 
observed effect. Consequently, researchers often relate the effect of a drug 
to the concentration in the sampling compartment, typically the plasma 
compartment, with some empirical account for the lag time. See [10] or [8], 
for instance. 
Moreover, methodology based on physiological compartmental models 
to directly account for the lag time suffers from practical and technical 
problems. That is, these models typically require more data to fit since they 
can involve a large number of unknown parameters, and they may not have a 
uniquely a priori locally or globally identifiable solution (see [3, 1, 16, 15, 2], 
and the sources found there in, for instance). However, even when sufficient 
data is available and a local unique solution could exist, these problem could 
be numerically unstable or ill-conditioned; for instance, minor error in the 
data can lead to bias in its prediction of the concentration of a drug in 
the unobserved compartments from data gathered in some intermediate 
compartment, see [17]. Methodology that does not properly accommodate 
any of the above issues can result in the miscalculation of the concentration 
in any compartment even more so in the unobserved compartments, see [6] 
for a particular illustration. 
In this paper, we will see that despite these technical issues, using a 
"simpler" model to predict concentration levels of a drug can both fail to 
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describe the data and, even when it does, it fails to predict the duration of 
the effects of a drug, so that a model which includes an effects compartment 
must be considered. We will also see that by employing the structure of the 
model, it is possible to fit a sequence of smaller problems and thereby fit a 
more numerically stable problem and reduce the data demands in terms of 
the number of unknown parameters. Using the one-compartment oral ab-
sorption model(lCOA model), we will compare the fit of the Theophylline 
data to that of the two-compartment oral absorption model(2COA model). 
Our data analysis and simulations indicate that it is possible to fit these 
models reliably; that is, our estimates have smaller mean-square error and 
standard deviations than the ordinary least squares method or when the 
structure of the model is disregarded, Moreover, this approach allows for 
randomness in the model parameters. Possible extensions of this method in-
clude the three-compartment mammillary or catenary model with sampling 
and input by necessity limited to the central compartment. 
This paper is organized as follows. In sections 2, 3, and 4, we give a 
brief introduction to compartmental models and their use in pharmacology. 
In sections 5, 6, and 7, we discuss estimation with these models and present 
the analysis of our approach. Lastly, we conclude with a summary of our 
findings, and in section 9 we established some identifiability results for the 
models considered in this paper. 
2 Preliminaries 
Because it is important for the reading of this paper, in the following three 
sections, we provide a brief introduction to compartmental models, discuss 
some of the common models within pharmacology, the role of the initial 
conditions to the system, the solutions to these problems and the relation-
ship these solutions have to the duration of an effect from an administered 
dose. 
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Not all compartmental models are physiologically based but rather are 
simplified versions of such models. For instance, one of the common ex-
periments in the pharmacokinetic literature consists of a single or a series 
of bolus injections into the plasma or into the gut, the later being referred 
to as first order absorption or oral administration of a drug, with sam-
pling typically occurring in the plasma compartment, see [10, 9]. That is, 
a drug's flow through the body is assumed to follow linear kinetics from 
its administration site, say compartment 1 with concentration ¢1 (arrows 
indicate direction of flow), to the sampling compartment p, and then to the 
targeted compartment n. It then returns to the plasma compartment from 
which it leaves the system. In the case of the oral absorption of a drug, this 
is indicated by the following diagram 
(2.1) 
where ¢i denotes the concentration in compartment i, aij the flow rate of 
the drug from compartment i to compartment j, and apo refers to the flow 
rate to the outside of the system from the pth compartment( corresponding 
to the arrow pointing out of cf;p), where the aij are nonnegative by necessity, 
see [1, 16]. 
Although our proposed estimation approach could be generalized to 
include other models in particular the first-order absorption experiment, 
we will concentrate on the following simplified version of diagram (2.1). 
That is, data limitations typically mean that one can only consider the 
case when n = 2 and p = 1 which gives the diagram corresponding to the 
one-compartment oral absorption model (from here on referred to as the 
1 GOA mode0 or the choice of n = 3 and p = 2 which gives the diagram 
corresponding to the two-compartment oral absorption model (from here on 
referred to as the 2COA model) to be considered in the next sections(note 
that in the compartmental analysis literature, these models correspond to 
two and three compartment models, respectively). 
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· Then, under the above assumptions, models based on diagram (2.1) can 
have closed form solutions. [4] obtained closed form solutions for various 
common pharmacokinetic experiments via the use of partial fractions and 
the Laplace transform. The reader is referred to [4] for details or to [9] 
or (10] for a summary of some of these solutions. However, as we will see 
in sections 5 and 6, if one is interested in estimation, then a closed-form 
solution to a system is not needed. Nonetheless, we point out that these 
solutions are special cases of a more general problem in compartmental 
analysis (see [1], [11], or [16] and the reference found there in). 
3 Compartmental models and pharmaco-
logic example 
A general compartmental system is described in vector notation as follows, 
dcp (t) 
dt 
cp(O) 
Acp(t) + Bu(t), t ~ 0 
0 
e(t) = ccp(t), 
(3.1) 
where cp is the concentration vector, u is the input vector, and e the obser-
vation vector. In scalar notation this is a system of n equations where the 
ith equation is given by 
In (3.1), A := [aij] is the n x n compartmental matrix representing inter-
action between compartments. Its entries are the unknown flow rates that 
are to be determined from a set of observations. 
To estimate these flow rates or parameters, an experiment is designed 
in which r inputs enter the compartments causing them to interact with 
one another. The r inputs are regarded as the (transposed) vector, u(t) = 
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(u1(t),uz(t), ... ,ur(t)), where u(t) is the input or forcing function. The 
paths by which the r inputs enter then compartments is represented by a 
n x r matrix B = [bik], called the input matrix where entry bik is positive 
if input uk(t) enters compartment i, and zero otherwise. Since it is usually 
not possible to sample each individual compartment, a q x n matrix C 
is introduced and called the sampling matrix. This matrix represents the 
paths from compartments to sampling devices where entry Cij is positive 
if compartment j influences output function component ei(t); otherwise 
Cij = 0. Then the response function is e( t) = (6 (t), 6( t), ... , eq ( t)). 
Typically, in experiments involving human subjects, both B and C con-
sists of multiples of the natural basis elements, ej, where compartment j 
is the only compartment receiving input or the only compartment being 
sampled. 
Some of the commonly used pharmacokinetic models are especial cases 
of a compartmental system. To see this, we consider a generalization of the 
models discussed in [10]. (In the Appendix, we establish that they are also 
identifiable). 
The system of differential equations resulting from diagram (2.1), as-
suming that ¢1 receives Iff units of bolus inputs administered at times ti, 
can be verified to consist of a bi-diagonal compartmental matrix A up to 
the sampling compartment, </Jp, after which the matrix is tri-diagonal. That 
is, from (3.2) we have that 
d¢1 (t) 
dt 
d¢2 (t) 
dt 
d¢p (t) 
dt 
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(3.3) 
difln (t) = an-l,nifln-1- an,n-lifln 
dt 
which can be rewritten as a system as in (3.1) 
d¢(t) = A¢(t) + Bu(t), 
dt (3.4) 
where 8(·) is the Dirac delta function, A is a tridiagonal nxn compartmental 
matrix, and Bu(t) = e1 Ei J?-8(t- ti) is the input or forcing function into 
compartment one or ¢1(t). Note that Di is the dose given at times ti while 
V is the. volume of the distribution. 
The volume of the distribution is a function of the clearance parameter, 
Cl, and the rate at which the drugs clears the plasma or the sampling 
compartment, see [9] for instance. Jointly they form the initial conditions 
to the system of differential equations (3.3) and (3.4); that is, for the 2COA 
model, 
Cl V=----
a2o + a23 
(3.5) 
Because it is important for the reading of this paper, with consider as 
examples of system (3.3) the lCOA and the 2COA models. From (3.4), we 
see that these models correspond to the following tridiagonal compartmen-
tal matrices with p = 1, n = 2 and with p = 2, n = 3, respectively. 
(3.6) 
and 
( 
-a12 0 
A2-cmpt = a12 -(a23 + a2o) 
0 a23 
(3.7) 
Moreover, considering the initial conditions to the system as the one 
time dose tf, (see, for instance, [17] and [6]) then the input function Bu(t) = 
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e 1 ~o(t) forms the initial conditions to the system, where D is the adminis-
tered one-time dose, V is the volume of the distribution, and with sampling 
matrix C = ef. This then can only have the following solutions. 
Through the method of variation of parameters [7], the formal solution 
to (3.1) and (3.4) can be found to be 
~(t) = C fat e(t-T)A Bu(T)dT, (3.8) 
for which with A as given in (3.6) or (3. 7) and C and B as previously 
discussed, (3.8) gives 
T AtD ~(t)=e2e ver, 
where eAt is the matrix exponential ([7, 16]). 
(3.9) 
4 Closed-form solutions and effective thresh-
old 
As we will see, for estimation purposes, it is not necessary to have a closed-
form solution to (3.8); however, the solutions do provide useful information 
if one is interested in analyzing the relative asymptotic behavior of the 
system. It is straightforward to see that the closed-form solution to the 
2COA model is as follows. 
From (3.9), we find that the concentration in compartment one in either 
the 1 COA or the 2COA model is 
where ~ are the initial conditions to the system. We next focus only on 
that for the 2COA model. 
To obtain the solution to the 2COA model, we solve for 1/;2(t) and ¢3(t) 
in (3.2) by treating the solution to compartment one as the forcing func-
tion in compartment two; that is, we then redefine the system by letting 
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(Bu(t))T = (~e-a12 t,o)T in (3.1) and consider the lower 2 x 2 block of 
A2-cmpt in (3.7), denoted by At, as the new compartmental matrix, that is, 
At= ( 
Then, the new system is 
which, assuming that -a and - f3 are the distinct eigenvalues of At and 
not equal to -a12 with 0 < f3 < a < a12, yields the solutions to the 2COA 
model found in several places including [17]. These solutions then are 
As we will see from (4.2), we can know infer about the asymptotic levels 
of the concentration in the unobserved compartment relative to that in the 
sampling compartment. To do this we first make the following definition. 
The effective threshold of a drug corresponds to the level of the drug in 
the targeted compartment. That is, a pre-specified value, say T, for which 
the concentration in the targeted compartment stays near T. In practice this 
level is difficult to estimate. As a result the level in the plasma compartment 
is used instead. However, this can suffer from drawbacks, in particular, it 
may not give correct indication as to the level in the unobserved compart-
ment of interest relative to that in the sampling compartment. To see this, 
we consider the behavior of ¢2(t) and ¢3 (t) for timet large enough in the 
two-compartment model. 
Since tis large enough, we can ignore the term involving e-at and e-al2t 
in ( 4.2) since they converge to zero more rapidly than e-f3t. This gives the 
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following asymptotic forms 
<h(t) (4.3) 
Hence, the ratio 
= 
a32- f3 (4.4) 
can provide some indication as to the asymptotic level of drug in the un-
sampled third compartment. That is, say the plasma level curve decreased 
before the effects compartment does (as is the case of Westlake's model in 
Table 1), then (4.4) indicates that this will be the case whenever the ratio 
is less than 1; or if 
However, this will follow whenever 
(4.5) 
To see this, note that since a12~ > 0 and 0 < f3 < a < a12, it follows 
that (a - {3) > 0 and ( a12 - {3) > 0 and the desired conclusion is reached. 
In practice one could check ( 4.5), or that the flow rate from compartment 
two to compartment three is greater than the flow rate from compartment 
three to compartment two. However, establishing an inequality for the 
case when the plasma clears slower than the targeted compartment is less 
obvious in terms of a sufficient conditions that the flow rates must meet; it 
is however feasible to check (4.4) since the eigenvalue f3 can be computed 
from knowledge of the estimated flow rates which we do in the next section. 
5 Estimation 
In the following three sections, we discuss our estimation approach, present 
the results of our simulation studies, and those of our data analysis. 
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Even for a well-posed experiment, or an experiment where apriori identi-
fiability of the flow rates has been established as discussed in the Appendix, 
numerical or statistical estimation, regardless of noise in the data, is non-
trivial even if the problem is identifiable. In this section we will consider 
the following hierarchical nonlinear modeling problem. 
Suppose one makes observations 
Yii = ,P(tij)(1 + Eij), i = 1, ... , m, j = 1, ... , mi, (5.1) 
where i represents the number of subjects and j the number of observations 
per subject, and Eij is the error term associated with observation ij. Since 
the error structure, in biological experiments, is argued to be multiplicative 
or to depend on the mean (see (8], for instance), the error then is assumed 
to distributed N(O, CJ2 1jJ ). 
Although other models are possible, for our analysis, we will only be 
considering the case when the model in (5.1) is as given in (3.9) or that is 
(5.2) 
where Ai corresponds to the matrix for the 2COA model given in (3.7) for 
the ith individual. The random effects are then assumed to follow 
(5.3) 
where, due to the nonnegativity of the entries of A, the error term entries 
of Ei are distributed log-normal with mean 0 and with covariance matrix 
R. 
Solving problem (5.1) with the model given in (5.2) and assuming (5.3) 
may not only require more data than the ordinary least squares approach to 
fit successfully (since for the 2COA model, it has 16 unknowns if we assume 
that R is unstructured and the initial conditions of the system are unknown 
as well) but it can only be solve approximately since the random effects and 
the nonlinearity of the model make it so that no closed form expression for 
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the marginal distribution can be found, so that approximation methods 
must be employed (See for instance [8] and (13] for details). 
We found no software that could directly handle problem (5.1) giVen 
(5.2) and (5.3); however, it is possible to handle this problem in the following 
manner. 
6 Dimension reduction estimation 
Although this approach could be generalized to include other models, m 
this we work we propose that the way to handle the nonlinear hierarchical 
problem discussed in this section is to regard the 2COA model as a combi-
nation of two simpler problems: the 1COA model and then handle the the 
remaining of the system as the two-compartment open model ([9]). This im-
plies that one is dealing with simpler hierarchical modeling problems both 
of which have been previously considered (see [13, 8, 12]). 
This approach can also be viewed as motivated by the manner in which 
the closed-form solution to the 2COA model is found in sections 3 and 4 or 
the way in which the identifiability results are established in the Appendix. 
That is, we propose that the data be used to estimate the parameters in 
the 1COA model and that once these quantities are estimated that they be 
held fixed in the remaining of the compartmental matrix A in (3.7), and 
that then the remaining entries of the lower block matrix, At, be estimated. 
That is, we first solve for a12, a2o + a23 in Al-cmpt, and ~ as given in 
(3.6) with the following model 
Step One 
D Y .. _ eTeAl-cmptt_e lJ - 2 v 1, (6.1) 
where e 1 and e2 are the two-dimensional canonical basis elements. Then 
holding a12, a2o+a23, and~ fixed, solve for the remaining entries of A2-cmpt 
with 
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Step Two 
(6.2) 
where e1 and e2 are now the three-dimensional canonical basis elements. 
In practice, for these problems typically an estimate of the initial con-
ditions, ~, is available so this should be used in Step One. Moreover, when 
' 
data is generated from a three compartment model, the estimate of the 
diagonal element of A1-cmpt may not be good since, as we will see in the 
next section(see Figure 2), this may fail to capture the decay of the con-
centration curve. Hence, we proposed that Step Two be modified to also 
estimate the diagonal of A2-cmpt so that the only entries of A2-cmpt to be 
held as fixed and known are a12, or the absorption rate into the plasma or 
the sampling compartment, and the initial conditions to the system, ~-
As our simulations and data analysis will show, n the estimation ap-
proach outlined in (6.1) and (6.2) can prove successful. 
7 Application and simulation 
In this section we report the results of our simulation and data analysis. 
Although we witnessed similar results for a larger class of matrices, in 
Table 1 and Table 2, we report the outcome for the matrix described in 
[17] and its computed ordinary least squares solution, and in Table 2, we 
simulate with the computed matrices of Table 5 and Table 3 as the true 
matrices. 
The simulations were done in Matlab using lsqnonlin for the least squares 
problem and the built-in matrix exponential function expm. The random 
effects data analysis was done in Splus using nlme and computing the spec-
tral decomposition for the matrix exponential. Table 1 consisted of 14 fixed 
time observations per data set and Table 2 of 11 observations out of 100 
data sets each generated with multiplicative a = .15 normal error 90% of 
13 
the time and u = .2 normal error the remaining 10% of the time. 
The data for both tables was simulated according to Method 1 which 
corresponds to the ordinary least squares fit of problem (5.1) and not ac-
cording to Method 2 corresponds to 'splitting' the estimation problem as 
outlined in Step One and Step Two. To inform on the numerical behavior 
of these problems, we report the mean condition number of the Jacobian 
at the computed solution for both methods and the quantity d. e. r. which 
corresponds to the mean estimate of the duration of effect ratio as reported 
in (4.4). Westlake's matrix corresponds to the simulated matrix reported 
in [17] and so do the chosen time points and initial conditions. Lastly, 
the Theophylline matrices corresponded to the nlme and the ordinary least 
squares fit of the Theophylline data reported in Table 5 and Table 3, re-
spectively. In Table 3, the initial conditions and time points correspond to 
the average values of the data set reported in Pinheiro and Bates (1995); 
that is, the initial conditions were computed by calculating the average over 
allll subjects of the value of weight/dose which were available per subject. 
Note that in both Table 1 and Table 2, Method 2 produces estimates that 
which have consistently smaller standard error and mean-square error than 
Method 2. This is significantly so for the parameters a23 and a32· Moreover, 
note that in Table 1 and in the second half of Table 2, despite the error 
in the simulated data, the mean condition number of the Jacobian(cond. 
# Jac.) is small so that the problem is numerically well-behaved for these 
matrices. However, if we consider the first half of Table 2, we see that while 
the estimates of Method 1 do tend to have smaller standard error and 
mean-square error than those of Method 1, Method 2 yields an estimate 
of the mean duration of the effects ratio(d.e.r.) which gives an erroneous 
indication as to which compartment is emptying out first relative to the 
third unsampled compartment, yet Method 1 does not. 
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Table 1: Westlake mtx simulated data:(OLS):I.C.=.441 
Method 1 Method 2 
True Value Mean SD MSE Mean SD MSE 
a12 2.388 2.546 .4877 .5101 2.2792 .4319 .4435 
azo .1689 .1663 .0166 .0167 .1623 .0162 .0174 
a23 .5413 .5832 .1856 .1894 .5335 .0906 .0905 
a32 .2503 .3016 .2256 .2302 .2311 .0754 .0774 
d.e.r. .3770 .4312 .3538 
cond. # Jac. 7.1492 6.9198 
a12 1.7459 1.8300 .4891 .4938 1.5285 .2347 .3190 
azo .2489 .2483 .0188 .0187 .2399 .0181 .0202 
a23 .8582 .9622 .8245 .8270 .7702 .1062 .1375 
a32 .3022 .3934 .5900 .5941 .2358 .0640 .0920 
d.e.r. .2874 .3429 .2449 
cond. # Jac. 9.7456 7.0217 
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Table 2: Theophylline mtx simulated data:OLS fit: 
Ave(I.C)=15. 7757 
Method 1 Method 2 
True value Mean SD MSE Mean SD MSE 
a12 .7040 .7487 .1303 .1372 .6252 .1097 .1346 
a2o .1086 .0928 .0361 .0392 .0819 .0389 .0470 
a23 .1442 .2512 .1952 .2217 .1416 .0414 .0413 
a32 .2326 .4263 .4834 .5185 .1483 .1054 .1345 
d.e.r. 1.2018 1.4768 .7919 
cond. # Jac. 1.168e+03 2.636e+03 
a12 1.2177 1.3393 .2388 .2669 .9323 .1741 .3339 
a2o .1278 .1225 .0149 .0157 .1203 .0116 .0138 
a23 .4220 .6890 .5879 .6430 .2170 .0742 .2179 
a32 .8290 1.2973 1.1576 1.2434 .3769 .1559 .4780 
d.e.r. 1.7709 1.7694 1.4122 
cond. # Jac. 31.1828 10.4211 
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In this table we report the ordinary least squares fit of the Theophylline 
data when the initial conditions of the system are assumed to be unknown; 
that is, the estimate of initial dose from the data is used but V as given in 
(3.5) is assumed to be unknown. To be consistent with this notation, we 
report this quantity as ct-1 in the table. The heading of 2COA(Method 1} 
corresponds to the fit of (5.1) when the matrix is as given in (3.7)(or when 
Step One and Step Two are not followed), and that of 1COA to that when 
the matrix is as given in (3.6). 
ct- 1 
a12 
azo 
az3 
a32 
d.e.r. 
con d. 
Table 3: Theophylline data:OLS fit: 
2COA(Method 1) 
I.C. unknown 
1COA 
Mean SD Mean SD 
7.3495 2.6237 25.4189 8.9747 
1.2177 .8708 1.9468 2.4357 
.1278 .0251 .3022 .4598 
.4220 .3760 
.8290 .6229 
1.7709 
# Jac. 3.5145e+04 1.84e+03 
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2COA model-Method 1 
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Figure 1: Results of Table 3. The '.' corresponds to the data, 'square' to the 
estimated fit, and the 'x' to the mean estimate. 
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In the following table we see that it is not possible to fit the one-
compartment oral absorption model to the Theophylline data since the 
estimates fail to capture the decay of the curve(see Figure 2); however, the 
numerical sensitivity of these problems is such that the 2COA model when 
the initial conditions are known could not be used to described subjects 
5, 10, 12 either. The estimates of the initial conditions used was that of 
weight/dose which were available per subject. In Table 4 we report these 
findings. 
Table 4: Theophylline data: OLS fit(I.C. known) 
2COA{Method 1) 1COA 
Mean SD Mean SD 
a12 1.1081 .6218 .8340 .5092 
a2o .1580 .0541 .2071 .1393 
a23 .7738 .9166 
a32 .7225 .4682 
d.e.r. .8404 
cond. # Jac. 12.8226 1.3355 
19 
2COA model-Method 1 
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Figure 2: Results of Table 4. The '.' corresponds to the data, 'square' to the 
estimated fit, and the 'x' to the mean estimate. 
20 
In Table 5 and Figure 3, we see that it is possible to fit random effects 
and describe all the data with the 2COA model if we follow the procedure 
outlined in Step One and Step Two or Method 2. We also use the fact that 
the initial conditions are known. The results are reported on a log scale, 
SD(fe) corresponds to the standard deviations of estimates for the fixed 
effects, and SD(re) corresponds to that of the random effects. Lastly, likrat 
corresponds to the reported likelihood ratio. 
Table 5: Theophylline data:nlme:I.C.=weight/dose 
2COA(Method 2) 1COA 
Mean SD(fe) SD(re) Mean SD(fe) SD(re) 
log(a12) -.3510 .1431 
log(a2o) -2.2197 .1714 
log(a23) -1.9366 .5198 
log(a32) -1.4585 .2963 
likrat -239.4758 
d.e.r. 1.2018 
.4518 
.4359 
1.6399 
.4732 
-.3510 
-1.7705 
-259.3699 
.1431 
.1922 
In Table 6, fix and rand correspond to the fixed correlation population 
coefficients and to those of the random effects, respectively. Entries are 
reported on a log scale. The 1COA{P&B) column corresponds to the cor-
relation coefficient estimates obtained by [13] when they considered a 12 
and the clearance parameter cl as random in their analysis(Note that cl is 
considered part of the initial conditions as discussed in sections 3 and 4.). 
Table 6 Correlation coefficients(nlme fit) 
.4518 
.6429 
2COA 1COA 1COA(P&B) 
fix rand fix rand fix rand 
(log( a2o, a23) .562 .976 (log(a12, k)) -.77 -.861 (log(a12, cl)) -.540 0 
(log( a2o, a32)) .685 .999 
(log(a23, a32)) .513 .969 
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Figure 3: Results of Table 5. The '.' corresponds to the data and the 'x' to the 
mean estimate. 
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8 Summary 
In this paper we discussed the need for models which include an effects or 
targeted compartment to directly account for the lag-time and the duration 
of the effect of a drug. We also presented some of the technical difficul-
ties associated with fitting these models, and for completeness and ease 
of reading we provided a brief introduction to compartmental models, and 
showed that some of the common models within the pharmacology litera-
ture form an identifiable subset of these models (see sections 2, 3, 4, and 
the Appendix). 
We have also seen that it is possible to fit the 2COA model success-
fully to both true and simulated data provided in part that the structure 
of the model is used or that the dimension of the problem is reduced as 
outlined in Step One and Step Two of section 6. However, we caution 
about generalizing these results to arbitrary compartmental matrices since 
in our simulations we found that the relative size of the magnitude of the 
flow rates plays a critical, yet not well-quantified, role in the estimation of 
these problems. In fact for the matrix of Table 5 or that in the first half 
of Table 2, we found that as we increased the value of the a 12 flow rate 
that the quantity d.e.r. approached one while the condition number of the 
Jacobian gradually decreased but still remained in the 1000's. Nonetheless, 
generally we found that the estimates given by Method 2 tended to have 
smaller standard error and mean-squared error than those of Method 1 or 
when the structure of the model was disregarded(see Table 1 and Table 2) 
and, perhaps less surprising, that Method 2 tended to be well-conditioned 
whenever Method 1 was. 
We have also seen that by employing the structure of the model, it is 
possible to allow for random effects in the estimates and thereby account 
for the variability within the data and the correlation structure. As Table 
5 and Table 6 indicate, our data analysis results are comparable to those 
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obtained by (13), except we make use of the fact that the initial conditions 
of the system are known since dose and the covariate of weight are available 
per subject in the Theophylline data set. This, then give an estimate of the 
initial conditions of the system as discussed in sections 2, 3, and 4. Since 
the initial conditions are known, we have also argued that the correct model 
to fit is the 2COA model rather than the 1COA as typically done, see [8) 
and [13). In fact, Table 3 and Figure 2 and Table 5 and Figure 3 indicate 
that the 1COA fails to capture the decay of the data so that a model which 
includes a third compartment must be included when the initial conditions 
to the system are known. 
More immediate future work includes extending the estimation approach 
outlined in Step One and Step two to include other common experiments 
within pharmacology such as those employing the three-compartment mam-
millary or catenary model with sampling and input limited to the central 
or second-compartment. 
9 Appendix 
In this section we show that the pharmacologic models discuss in sections 
2, 3, and 4 form part of a larger class of identifiable models. However, we 
first define what its meant by identifiable. 
We say a system is identifiable if for a hypothetically error free exper-
iment (error free both in the data and in the model structure), a sam-
pling and input matrix is given and the structure of A is correspondingly 
well-specified so that the necessary conditions for a unique global or local 
solution to the model parameters are met, see [1). 
Claim 1 It is possible to identify all the entries of A in system (3.3) for a 
general known input function u(t) with input matrix B = e 1 and sampling 
matrix c = er. 
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Note that in Claim 1 the choice of p = 1 or p = 2 and n = 4 and Bu(t) = 
e1(dose)8(t) includes the class of models considered by [10]. 
Corollary 1 Claim 1 holds for a compartmental matrix A where At has a 
mammillary structure or one where At only has nonzero entries on its first 
row, first column, and diagonal. 
Proof of Claim 1: 
The method of proof that we will follow consists of breaking up the problem 
into two pieces. Similar to the example previously considered, we will first 
analyze the compartmental matrix only up to the sampling compartment 
p, showing that this portion is identifiable; that is, labeling the upper block 
of A, Au, where Au is the p x p upper bi-diagonal block of A. The solu-
tion to this part of the problem will then form the forcing function into 
compartment p. 
We first establish the claim for the case p = 2. Then the sampling 
matrix is C = e~ and the unit bolus input function Bu(t) = e1 u(t). Then 
this gives the impulse-response function 
whose Laplace transform is 
Thus, we see that knowledge of this function determines a2o and a 12 u-
niquely and hence this system is identifiable. 
To see if this same choice of C and B allows for the identification of all 
the rates for a general p, the reader can verify that the (p, l)th_entry of the 
matrix (sf- Au)-1 is 
(s + a12)(s + a23) ... (s + ap-2,p-l)(s + ap-l,p)(s + apo) · 
From the above, we see that the numerator is a scalar while the denomi-
nator is a polynomial in s of degree p, this then results in p + 1 equations 
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in terms of the unknown flow rates; hence, it is possible to identify p + 1 
unknowns from the chosen experiment. Thus, the experiment is identifiable 
up to this point. 
To see that the entire system is identifiable, we proceed by considering 
the solution ap-I,p</Jp-l (t) of the p-lth compartment as the forcing function 
into the pth compartment. That is, we take C = e~ and let Bu(t) = e1 </Jp(t). 
Then to see that the remaining portion is identifiable, we recognize the 
remaining lower block of the compartmental matrix, A1, as catenary or tri-
diagonal, for which, [3] established that with this new choice of input matrix 
B and sampling matrix C, that it is possible to identify all of the entries of 
A1. This together with the previous result gives us the result that all of A 
is identifiable. Hence the claim is established. 
Proof of Corollary 1: 
The result follows in a similar fashion to Claim 1 and from considering [3] 
work pertaining to mammillary matrices or matrices which have nonzero 
entries only on their first row, first column, and diagonal. 
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